Cosmetics containing ceramide-containing niosomes
Patent Information
- Application Number
- JP2020159814
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-09-24
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2040-09-24
AI Technical Summary
【0009】 本発明の皮膚外用組成物に含有されるニオソームは、通常の状態では、安定な2重膜ベシクルとして挙動する。このため、これを含有する外用組成物中では、ニオソームの2重膜中にセラミドが安定に保持され、セラミドの結晶が析出しない。しかし、皮膚の温度とpH条件で安定なニオソームが崩壊すると、このニオソームを構成している成分であるセラミドが放出される。 皮膚の温度とpHで崩壊したニオソームから放出されたセラミドは、皮膚角層中で放出されると、角層のラメラ構造に組み込まれて、ラメラ構造の形成を促進するため、皮膚のバリア機能をより強化する。このため、本発明のニオソームを含有する組成物は、従来の技術では困難であった、セラミドによる皮膚バリア機能の強化を達成することが可能となる。 本発明のニオソームは、セラミド類とポリメタクリル酸のカルボキシル基の一部がメトキシジエチレングリコールおよびラウロキシテトラエチレングリコールによりエステル化された構造を有する共重合体を含んでいる。このニオソームは、皮膚の温度とpHで崩壊する。
Smart Images

Figure 0007585564000005 
Figure 0007585564000006 
Figure 0007585564000007
Abstract
Description
[Technical field]
[0001] The present invention relates to a cosmetic preparation comprising ceramide-containing niosomes. [Background technology]
[0002] Ceramide is a compound formed by an amide bond between sphingosine and a fatty acid, and is found in large amounts in cell membranes. Ceramide is the main component of the lamellar structure formed by intercellular lipids in the stratum corneum of the skin, and plays an important role in the skin barrier function. For this reason, it is often incorporated into cosmetics to improve the skin barrier function. However, because ceramide is highly crystalline, it is difficult to stably incorporate it into cosmetics as is. It is particularly difficult to incorporate it into cosmetics that contain little oil, such as lotions.
[0003] In order to stably incorporate ceramide into a lotion, it is necessary to complex the ceramide with a micelle or vesicle, i.e., a vesicular structure formed by surfactants, phospholipids, etc. However, when ceramide is stably complexed as a component of a micelle or vesicle structure, the structure is maintained even when applied to the skin, so that the ceramide cannot be supplied to the inside of the stratum corneum of the skin, and the expected beneficial functions of ceramide may be lost.
[0004] Among vesicles, a bilayer endoplasmic reticulum structure similar to liposomes formed by nonionic surfactants has been attracting attention in recent years. This endoplasmic reticulum is called a "niosome." Niosomes are closed endoplasmic reticulum (vesicles) with a bilayer membrane mainly composed of nonionic surfactants, and like liposomes made of phospholipids, they are used in drug delivery systems (DDS) and cosmetics. Patent Documents 1 and 2 describe niosomes containing ceramide as a component of the bilayer membrane in a complex, and cosmetics containing the niosomes.
[0005] Patent Document 3 discloses a copolymer and a liposome complex having temperature and pH responsiveness. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] JP 2007-246538 A [Patent Document 2] Special Publication No. 2010-513221 [Patent Document 3] JP 2015-209494 A Summary of the Invention [Problem to be solved by the invention]
[0007] An objective of the present invention is to provide a composition for external use on the skin containing niosomes that have the function of disintegrating under specific temperature and pH conditions to release ceramide, and niosomes. [Means for solving the problem]
[0008] The present invention comprises the following configuration. 1. A composition for external use on the skin comprising niosomes comprising the following (A) to (E): (A) A copolymer having a structure in which some of the carboxyl groups of polymethacrylic acid are esterified with methoxydiethylene glycol and lauroxytetraethylene glycol. (B) Ceramides (C) Nonionic surfactants (D) Polyhydric alcohol (E)Water 2. The topical skin composition described in 1, in which (A) the copolymer having a structure in which some of the carboxyl groups of polymethacrylic acid are esterified with methoxydiethylene glycol and lauroxytetraethylene glycol has an average molecular weight of 1,000 to 1,000,000. 3. A topical skin composition described in 1 or 2, wherein (C) the nonionic surfactant contains both polyoxyethylene hydrogenated castor oil and sorbitan fatty acid. 4. The topical skin composition described in 3, wherein the polyoxyethylene hydrogenated castor oil is polyoxyethylene hydrogenated castor oil having an average degree of polymerization of polyoxyethylene chains of 60 to 100, and the fatty acid sorbitan is one or more selected from sorbitan sesquiisostearate, sorbitan sesquioleate, and sorbitan oleate. 5. A composition for topical application to the skin described in any one of 1 to 4, wherein (D) the polyhydric alcohol is either dipropylene glycol or pentylene glycol or both. 6. The composition for external use on the skin according to any one of 1 to 5, wherein the composition for external use on the skin is in the form of a lotion. 7. Niosomes containing a copolymer having a structure in which some of the carboxyl groups of polymethacrylic acid are esterified with methoxydiethylene glycol and lauroxytetraethylene glycol and ceramides complexed in a bilayer membrane. 8. The niosome according to 7, wherein the copolymer having a structure in which a portion of the carboxyl groups of polymethacrylic acid is esterified with methoxydiethylene glycol and lauroxytetraethylene glycol is a random copolymer. 9. The niosome according to 7 or 8, wherein the methoxydiethylene glycol (MDEGMA) portion and the lauroxytetraethylene glycol (LTEGMA) portion of the copolymer having a structure in which a portion of the carboxyl groups of polymethacrylic acid is esterified with methoxydiethylene glycol and lauroxytetraethylene glycol are 50 to 70% and 2 to 10%, respectively, when the entire carboxyl groups of polymethacrylic acid are taken as 100%. Effect of the Invention
[0009] The niosome contained in the skin external composition of the present invention behaves as a stable bilayer vesicle under normal conditions. Therefore, in the external composition containing it, ceramide is stably held in the bilayer of niosome, and ceramide crystals do not precipitate. However, when the stable niosome is broken down under the temperature and pH conditions of skin, ceramide, which is a component constituting this niosome, is released. When the ceramide released from the niosomes disintegrated by the temperature and pH of the skin is released in the stratum corneum, it is incorporated into the lamellar structure of the stratum corneum and promotes the formation of the lamellar structure, thereby further strengthening the barrier function of the skin. Therefore, the composition containing the niosomes of the present invention can achieve the strengthening of the skin barrier function by ceramide, which was difficult to achieve with conventional techniques. The niosome of the present invention contains a copolymer having a structure in which a part of the carboxyl group of ceramides and polymethacrylic acid is esterified with methoxydiethylene glycol and lauroxytetraethylene glycol. This niosome disintegrates at the temperature and pH of the skin. [Brief description of the drawings]
[0010] [Figure 1] FIG. 2 is a schematic diagram showing a synthesis reaction process of a copolymer. [Diagram 2] FIG. 1 is a schematic diagram showing the structure of a niosome of the present invention and a schematic diagram showing the collapse principle of a niosome. [Diagram 3] 1 is a graph showing the results of particle size measurement of particles contained in a composition carried out in Test Example 3. [Figure 4] This is a microscopic observation image of stable niosomes in Test Example 3. An enlarged image of the circled portion in the figure is shown overlapping the rectangular frame. [Diagram 5] FIG. 1 is a microscopic observation image of collapsed niosomes in Test Example 4. [Figure 6] 1 is a graph showing the results of a test of ceramide release temperature from niosomes of the compositions of Example 1 and Comparative Example 1 at pH 5, performed in Test Example 5. [Figure 7] 1 is a graph showing the test results of a human stratum corneum lamella formation test in Test Example 6. [Figure 8] 1 is a graph showing the results of a moisture retention test carried out in Test Example 7. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] The topical skin composition of the present invention is a composition containing niosomes containing (A) a copolymer having a structure in which a portion of the carboxyl groups of polymethacrylic acid is esterified with methoxydiethylene glycol and lauroxytetraethylene glycol, (B) ceramides, (C) a nonionic surfactant, (D) a polyhydric alcohol, and (E) water. Each component will be explained below. (A) A copolymer having a structure in which some of the carboxyl groups of polymethacrylic acid are esterified with methoxydiethylene glycol and lauroxytetraethylene glycol. In this specification, (A) a copolymer having a structure in which a portion of the carboxyl groups of polymethacrylic acid is esterified with methoxydiethylene glycol and lauroxytetraethylene glycol is simply referred to as a "copolymer". The copolymer has a structure in which the carboxyl groups of polymethacrylic acid are esterified with methoxydiethylene glycol (MDEGMA) and lauroxytetraethylene glycol (LTEGMA).
[0012] The copolymer has the repeating structure shown in Chemical Formula 1 below. [ka] where l, m, and n are the bond numbers of each residue. (chemical formula 1)
[0013] The copolymer can be prepared by synthesis using a known method. For example, a copolymer having a desired average molecular weight and esterification rate can be easily synthesized based on the method disclosed in Patent Document 3. This copolymer has a hydrophilic random coil structure under conditions of near-neutral pH and room temperature, and a hydrophobic globule structure under conditions of acidic pH of near pH 5 and 32°C on the skin surface.
[0014] The esterification ratios of methoxydiethylene glycol and lauroxytetraethylene glycol in the copolymer are preferably 50 to 70% and 2 to 10%, and more preferably 55 to 60% and 2 to 5%, respectively, when the total amount of carboxyl groups contained in the original polymethacrylic acid is taken as 100%, in terms of the binding rates of methoxydiethylene glycol (MDEGMA) and lauroxytetraethylene glycol (LTEGMA) per copolymer. In the present invention, the (A) copolymer is contained in the niosome-containing composition of the present invention in an amount of 0.01 to 10.0% by mass, preferably 0.1 to 5.0% by mass, and particularly preferably 0.3 to 1% by mass, based on the total amount. Furthermore, the composition containing the niosome of the present invention contains the (A) copolymer in an amount of preferably 0.1 to 10.0 parts by mass, more preferably 0.5 to 5.0 parts by mass, per 1 part by mass of the (B) ceramides. The number average molecular weight of the copolymer is not particularly limited, but is preferably from 1,000 to 1,000,000, more preferably from 15,000 to 40,000, and particularly preferably from 20,000 to 30,000.
[0015] (B) Ceramides The ceramides used in the present invention include ceramide, ceramide derivatives, and ceramide analogues. Ceramide is an amide derivative that accounts for about 50% of the intercellular lipids present in human skin (stratum corneum). Examples of ceramide include N-acylsphingosine (ceramide), N-acyldiohydrosphingosine (dihydroceramide), and N-acylphytosphingosine (phytoceramide). The chemical name of the aforementioned sphingosine is (2S,3R,4E)-2-amino-4-octadecene-1,3-diol, the chemical name of dihydrosphingosine is (2S,3R)-2-aminooctadecane-1,3-diol, and the chemical name of phytosphingosine is (2S,3S,4R)-2-amino-1,3,4-octadecanetriol. The ceramides contained in the composition containing the niosome of the present invention are preferably those generally used in cosmetics among external skin preparations, and more preferably those called poorly soluble ceramides. Examples of such ceramides include ceramides 1 to 6. The ceramides can be used alone or in combination of two or more. Ceramides 2 and 3 are particularly preferred. The chemical name of ceramide 2 is (2S,3R)-2-octadecanoylaminooctadecane-1,3-diol, and a commercially available product (Ceramide TIC-001 manufactured by Takasago International Corporation) can be used. The chemical name of ceramide 3 used in the present invention is 2-octadecanoylamino-1,3,4-octadecanetriol, and a commercially available product (DS-CeramideY3S manufactured by DOOSAN Corporation) can be used. The ceramides in the present invention are contained in the composition containing the niosomes of the present invention in an amount of preferably 0.01 to 5.0% by mass, more preferably 0.05 to 1.0% by mass, and particularly preferably 0.1 to 0.5% by mass, based on the total amount.
[0016] (C) Nonionic surfactants The non-surfactant used in the composition of the present invention may be any one that is generally used in cosmetics or topical preparations. Specifically, polyoxyethylene alkyl ethers (laureth-4, laureth-7, laureth-9, laureth-21, laureth-23, ceteth-10, ceteth-20, steareth-2, steareth-20, steareth-21, ceteareth-25, beheneth-20, beheneth-30, oleth-2, oleth-10), polyoxyethylene steryl ethers (PEG-5 phytosterol, PEG-10 phytosterol, PEG-30 phytosterol), polyoxyethylene fatty acid esters (PEG-25 stearate, stearyl esters ... PEG-40 stearate, PEG-45 stearate, PEG-55 stearate, PEG-75 stearate, PEG-100 stearate, PEG-150 stearate, PEG-150 distearate), polyoxyethylene polyhydric alcohol fatty acid esters (PEG-7 glyceryl coconut oil fatty acid, PEG-8 glyceryl isostearate, PEG-20 glyceryl isostearate, PEG-60 glyceryl isostearate, PEG-20 glyceryl triisostearate, sorbeth-30 tetraoleate, tetra Sorbeth-40 oleate, Sorbeth-60 tetraoleate), Polyoxyethylene hydrogenated castor oil (PEG-10 hydrogenated castor oil, PEG-20 hydrogenated castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-100 hydrogenated castor oil), Polyoxyethylene sorbitan fatty acid ester (Polysorbate 20, Polysorbate 60, Polysorbate 80), Glycol fatty acid ester (PG stearate, Glycerin fatty acid ester, Glyceryl stearate, Glyceryl stearate (SE), Isostearate Glyceryl phosphate, glyceryl oleate, glyceryl behenate), fatty acid sorbitan esters (sorbitan laurate, sorbitan palmitate, sorbitan stearate, sorbitan isostearate, sorbitan oleate, sorbitan sesquistearate, sorbitan sesquiisostearate, sorbitan sesquioleate, sorbitan trioleate, sorbitan tristearate, sorbitan olivate, sorbitan coconutate), sucrose fatty acid esters (sucrose laurate, sucrose palmitate,Sucrose stearate, sucrose coconutate), polyglycerin fatty acid esters (polyglyceryl-2 laurate, polyglyceryl-2 stearate, polyglyceryl-2 oleate, polyglyceryl-2 isostearate, polyglyceryl-4 isostearate, polyglyceryl-10 laurate, polyglyceryl-10 myristate, polyglyceryl-10 stearate, polyglyceryl-10 oleate, polyglyceryl isostearate Examples of such fatty acids include polyglyceryl-10, polyglyceryl-2 diisostearate, polyglyceryl-3 diisostearate, polyglyceryl-10 diisostearate, polyglyceryl-6 polyricinoleate, fatty acid alkanolamides (cocamide DEA, cocamide MEA, lauramide DEA), alkyl glycosides (caprylyl / capryl glucoside, decyl glucoside, lauryl glucoside, cetearyl glucoside, coconut oil alkyl glucoside). In the present invention, a combined use of polyoxyethylene hydrogenated castor oil and fatty acid sorbitan is preferred.
[0017] Polyoxyethylene hydrogenated castor oil The polyoxyethylene hydrogenated castor oil used in the present invention has an average degree of polymerization of polyoxyethylene chains of preferably 60-100, more preferably 80-100, and particularly preferably 100. If the average degree of polymerization of the polyoxyethylene chain is less than 60, the stability over time may be insufficient. The polyoxyethylene hydrogenated castor oils can be used alone or in combination of two kinds, as required. As the polyoxyethylene hydrogenated castor oil, commercially available products (POE(100) hydrogenated castor oil (NIKKOL HCO-100) manufactured by Nippon Surfactant Industry Co., Ltd., POE(100) hydrogenated castor oil (EMALEX HC-100) manufactured by Nippon Emulsion Co., Ltd., POE(80) hydrogenated castor oil (NIKKOL HCO-80) manufactured by Nippon Surfactant Industry Co., Ltd., etc.) can be preferably used.
[0018] Sorbitan fatty acids The fatty acid sorbitan in the present invention is also called sorbitan fatty acid ester. As the sorbitan fatty acid ester, a fatty acid having 8 to 22 carbon atoms can be ester-bonded to sorbitol. Suitable for the present invention is sorbitan sesquiisostearate, sorbitan sesquioleate, or sorbitan oleate, preferably sorbitan sesquiisostearate or sorbitan sesquioleate, more preferably sorbitan sesquioleate. Examples of commercially available sorbitan sesquiisostearate include NIKKOL SI-15RV (Nikko Chemicals Co., Ltd.) and Cosmol 182V (The Nisshin Oillio Group, Ltd.), and examples of commercially available sorbitan sesquioleate include Rheodol AO-15V (Kao Corporation) and Cosmol 82 (The Nisshin Oillio Group, Ltd.). Examples of commercially available sorbitan oleate include Rheodol AO-10V (Kao Corporation). Moreover, the above-mentioned fatty acid sorbitan can be used alone or in combination of two kinds, if necessary.
[0019] When the composition of the present invention contains polyoxyethylene hydrogenated castor oil and fatty acid sorbitan as the nonionic surfactant of component (C), the ratio of polyoxyethylene hydrogenated castor oil to fatty acid sorbitan is 2 parts by mass or less per part by mass of fatty acid sorbitan, more preferably 0.5 parts by mass or less, particularly preferably 0.3 parts by mass or less of polyoxyethylene hydrogenated castor oil per part by mass of fatty acid sorbitan. In addition, the composition containing the niosome of the present invention contains the nonionic surfactant (C) component in an amount of preferably 0.5 to 20.0 parts by mass, more preferably 1 to 10.0 parts by mass, and particularly preferably 2.0 to 6.0 parts by mass of (C) per 1 part by mass of the ceramides (B).
[0020] (D) Polyhydric alcohol The composition containing niosomes of the present invention contains (D) a polyhydric alcohol. As the polyhydric alcohol, it is preferable to contain dipropylene glycol or pentylene glycol, or both of them. When dipropylene glycol is contained, the content of the polyhydric alcohol is 20 parts by mass or more per part by mass of ceramides. When pentylene glycol is contained, it is preferable to contain 15 parts by mass or more per part by mass of ceramides. When both polyhydric alcohols are contained, the content ratio of dipropylene glycol to pentylene glycol is obtained, and based on this, it is confirmed that the content of ceramides meets the standard. When the content of dipropylene glycol or pentylene glycol is less than the above amount relative to the ceramide, crystallization of the ceramide may occur.
[0021] (E)Water The composition containing niosomes of the present invention contains water as an essential component. Water is an important component for forming niosomes. When the composition containing niosomes of the present invention is 100% by mass, the remaining amount of the total amount of the above components and the optional components of (F) is the water content. The content of water in the composition containing niosomes is preferably 50% by mass or more, more preferably 70% by mass or more, and particularly preferably 80% by mass or more. The content of water contained in the composition containing niosomes of the present invention can be adjusted by the content of optional component (F).
[0022] (F) Optional component The composition containing the niosome of the present invention can contain various components contained in skin external preparations and cosmetics, as long as the effect of the present invention is not impaired.The composition containing the niosome of the present invention can contain optional components, as long as the effect of the present invention is not impaired, that are usually used in cosmetics, such as organic powders, water-soluble polymers, salts, pH adjusters, preservatives, sequestering agents, medicinal ingredients, fragrances, etc.In addition, cosmetic ingredients such as ascorbic acid derivatives and plant extracts can be added.
[0023] As the organic powder, polymer beads such as polymethylmethacrylate resin (PMMA), silicone resin powder such as polysilicone 1 crosspolymer, polyurethane powder, etc. can be blended.
[0024] Examples of water-soluble polymers include gum arabic, gum tragacanth, galactan, guar gum, carrageenan, pectin, agar, quince seed, dextran, pullulan, carboxymethyl starch, collagen, casein, gelatin, methylcellulose, methylhydroxypropylcellulose, hydroxyethylcellulose, sodium carboxymethylcellulose, sodium alginate, and carboxyvinyl polymer.
[0025] Examples of salts include sodium chloride and magnesium sulfate.
[0026] Examples of pH adjusters include citric acid, sodium citrate, phosphoric acid, and sodium phosphate.
[0027] Examples of preservatives include methylparaben and ethylparaben.
[0028] Examples of sequestering agents include disodium ethylenediaminetetraacetate, edetic acid, and edetate salts such as sodium edetate.
[0029] Examples of medicinal ingredients include vitamins such as vitamin A oil, vitamin A such as retinol, vitamin B6 such as riboflavin, vitamin B6 such as pyridoxine hydrochloride, vitamin C such as L-ascorbic acid, L-ascorbic acid phosphate, L-ascorbic acid monopalmitate, L-ascorbic acid dipalmitate, L-ascorbic acid-2-glucoside, pantothenic acids such as calcium pantothenate, vitamin D such as vitamin D6 and cholecalciferol, vitamin E such as α-tocopherol, tocopherol acetate, and DL-α-tocopherol nicotinate, etc. Examples of the medicinal ingredients include water-soluble organic solvents such as ethanol, chelating agents, whitening agents, emollients, moisturizing agents, antioxidants, coloring agents, preservatives, fragrances (including essential oils), various oily components, and various aqueous components.
[0030] To prepare a composition containing niosomes of the present invention, for example, dissolve the copolymer of component (A) in water (E) and adjust the pH to 10 with a pH adjuster such as potassium hydroxide, then heat and heat to about 85°C, and add dropwise the components (B), (C), and (D) that have been uniformly heated and dissolved at about 85°C while stirring, and cool to 30°C using an ice bath, and then adjust the pH to 6.5 using citric acid as a pH adjuster. The heating temperature when mixing each component should not be lower than 80°C. In addition, the heating temperature is preferably lower than 90°C to prevent oxidation and denaturation. Thus, by heating and stirring, it is possible to obtain a composition containing the niosomes of the present invention in which niosomes containing ceramides in the niosome structure are dispersed. This composition is extremely stable at room temperature or low temperature without separation of the contained niosomes or niosome components or change in viscosity of the composition. The specific form of the composition containing the niosome of the present invention is suitably a liquid formulation such as a lotion, milky lotion, or cream.
[0031] The niosomes produced in the above process are composed of vesicles made of a double membrane of a nonionic surfactant, and a copolymer (copolymer) having a structure in which a part of the carboxyl group of polymethacrylic acid is esterified with methoxydiethylene glycol and lauroxytetraethylene glycol. This copolymer protrudes from the surface of the niosome as a hydrophilic random coil under conditions of room temperature and pH 6.5 (a cross-sectional view of the niosome of the present invention is shown in the schematic diagram of FIG. 2). When the niosomes come into contact with the skin, as shown in the lower part of FIG. 2, the hydrophilic coil becomes a hydrophobic spherical polymer (hereinafter referred to as "globule") due to the temperature and pH of the skin. As a result, the niosomes collapse due to hydrophobic interactions (see the lower part of FIG. 2), and the ceramide constituting the niosomes is released, and this ceramide is directly dispersed in the stratum corneum of the skin.
[0032] That is, when the niosomes contained in the composition of the present invention are applied to the skin or used externally, the three-dimensional structure of the copolymer changes from hydrophilic random coil to hydrophobic globule depending on the temperature and pH of the skin, and the niosomes gradually collapse, releasing ceramides. The released ceramides are dispersed in the stratum corneum of the skin and strengthen the lamellar structure of the stratum corneum.
[0033] A more specific explanation of the principle by which the bilayer membrane of niosomes is destroyed is as follows. In an aqueous dispersion of a niosome complex, under conditions in which the copolymer can maintain its hydrophilicity, the copolymer is stably present in water in a state supported by the niosome. When the copolymer becomes hydrophobic with a change in temperature and / or pH of this aqueous dispersion, the copolymer aggregates in water to form hydrophobic globules. In the niosome complex, since the copolymer is supported by the niosome, this conformational change of the copolymer occurs near the surface of the niosome bilayer. The globules, which are aggregates of the hydrophobic copolymer, penetrate into the lipophilic portion of the nonionic surfactant bilayer, destroying the bilayer.
[0034] The niosome of the present invention has a double membrane vesicle structure formed by complexing at least (A) a copolymer, (B) a ceramide, and (C) a nonionic surfactant, and contains (D) a polyhydric alcohol and (E) water within the vesicle. Niosomes containing the copolymer and ceramides complexed in a double membrane of a nonionic surfactant contain (A) the copolymer, (B) the ceramides, and (C) the nonionic surfactant in a ratio of preferably 0.01 to 3, more preferably 0.04 to 2, and particularly preferably 0.1 to 1, and preferably 0.5 to 10, more preferably 1 to 6, and particularly preferably 2 to 4, of the (B) ceramides and the (C) nonionic surfactant, when the mass of the (A) copolymer is taken as 1.
[0035] The nonionic surfactant (C) contained in the niosome can be any nonionic surfactant used in cosmetics, but it is preferable to use polyoxyethylene hydrogenated castor oil and fatty acid sorbitan in combination. The polyoxyethylene hydrogenated castor oil is preferably one having an average degree of polymerization of polyoxyethylene chain of 60 to 100, and the fatty acid sorbitan is preferably one or more selected from sorbitan sesquiisostearate, sorbitan sesquioleate, and sorbitan oleate. When polyoxyethylene hydrogenated castor oil and fatty acid sorbitan are blended, the content ratio of fatty acid sorbitan is preferably 0.4 to 16, more preferably 1 to 8, and particularly preferably 2 to 6, when polyoxyethylene hydrogenated castor oil is taken as 1.
[0036] Examples of the ceramides contained in the niosome include ceramides 1 to 6. The ceramides can be used alone or in combination of two or more. Among them, ceramide 2 or ceramide 3 is particularly preferred. EXAMPLES
[0037] The present invention will be described in more detail below with reference to Test Examples and Examples. <Test Example 1: Synthesis of copolymer> 1. Synthesis of copolymer The copolymer was synthesized by the method described in Patent Document 3. A schematic diagram of the reaction process is shown in FIG. 1. That is, 64.1 g of methoxydiethylene glycol methacrylate (MD), 21.6 g of methacrylate (MAA), 14.4 g of lauroxytetraethylene glycol methacrylate (LT), and 1.94 g of dipropyl peroxydicarbonate were dropped into distilled isopropanol (100 g) under a nitrogen atmosphere and allowed to stand at 60° C. for 2 hours. The solution was heated to 80° C. under a nitrogen atmosphere and reacted for 1 hour. The copolymer was recovered by freeze-drying. The yield of the copolymer was 99.8 g (97.8%). The number average molecular weight (Mn), weight average molecular weight (Mw) and polydispersity index (Mw / Mn) of the obtained copolymers were determined by GPC using THF as the mobile phase. The composition of the polymers was determined by proton NMR.
[0038] 2. Properties of the copolymer The copolymer is synthesized by radical copolymerization of MD, MAA, and LT, and thus has carboxyl groups, oligoethylene glycol groups, and hydrophobic groups. The composition and molecular weight of these functional groups were evaluated by NMR and GPC, respectively, and the results are shown in Table 1 below. As a result, the functional group ratios of MD, MAA and LT in the copolymer could be roughly controlled by the amount of monomer added. The number average molecular weight of the obtained copolymer was about 22,000. The polydispersity of the copolymer was 2.7, which is relatively high because it was a radical polymerization. The molecular weight of the copolymer can be controlled by adjusting the reaction time.
[0039] [Table 1]
[0040] The functional group ratio of the obtained copolymer could be roughly controlled by the amount of monomer added. The number average molecular weight of the obtained copolymer was about 22,000. The polydispersity of the copolymer was 2.7, which is relatively high because it was a radical polymerization. This copolymer was used in the following tests.
[0041] <Test Example 2: Preparation of compositions of Example 1 and Comparative Example 1> A composition containing niosomes of the present invention (Example 1) and a composition containing niosomes not containing a copolymer (Comparative Example 1) were prepared using the copolymer prepared in Test Example 1. The compositions of each are shown in Table 2 below. The composition is prepared by conventional methods.
[0042] [Table 2]
[0043] The compositions of Example 1 and Comparative Example 1 were adjusted to two different pH values, pH 5 and pH 6.5, respectively. The particle size of Example 1 and Comparative Example 1 adjusted to pH 6.5 was measured by dynamic light scattering, and all compositions showed a monomodal particle size distribution. From this result, it was revealed that the composition containing sorbitan sesquioleate and polyoxyethylene hydrogenated castor oil spontaneously formed niosomes with stable curvature, regardless of the presence or absence of copolymer. In addition, all the obtained compositions were stable solutions.
[0044] <Test Example 3: Stability test over time> 1. Test Method The stability over time of Example 1 and Comparative Example 1 adjusted to pH 6.5 was evaluated by storing them for one month in thermostatic chambers set at 5, 25, 40, and 50° C. After the specified time had passed, the average particle size of various niosomes formed was measured by dynamic light scattering, and the change in particle size was used as an index of stability.
[0045] 2.Results The particle size measurement results are shown in FIG. Both Example 1 and Comparative Example 1, which were adjusted to pH 6.5, showed a single-peak particle size distribution measurement result in all temperature ranges, and it was found that they had temperature stability. The pH 6.5, which is the preparation condition of the test sample, is assumed to be a weakly acidic lotion. In other words, in the case of a cosmetic material with a pH of 6.5, it was confirmed that the niosomes containing sorbitan sesquioleate and polyoxyethylene hydrogenated castor oil as nonionic surfactants were stable.
[0046] <Test Example 4: pH condition and temperature stability test of skin surface> 1. Test Method A solution of the composition of Example 1 adjusted to pH 5.0, which is the pH condition of the human skin surface, and a solution having the composition of Comparative Example 1 similarly adjusted to pH 5.0 were stored for 8 hours in thermostatic chambers set at 5, 25, and 40°C, respectively. After storage, particle size measurements were performed using dynamic light scattering and microscopic observations were performed. The responsiveness to pH and temperature was evaluated based on changes in particle size and appearance under microscopic observation. For comparison, the composition of Example 1 and the composition of Comparative Example 1 were each adjusted only to pH 6.5 and stored at 25° C. for 8 hours. The composition of Example 1 stored at pH 6.5 and 40° C. for 8 hours was also observed under a microscope.
[0047] 2.Results The particle size measurement results are shown in FIG. Furthermore, images obtained by microscopic observation are shown in FIG. 4 and FIG. The average particle size of the comparative composition did not change regardless of pH and temperature.This result shows that the niosomes contained in the comparative composition, i.e., the niosomes that do not contain copolymers, did not respond to condition changes even when placed under the condition of pH 5.0, which is the pH of skin, and at a temperature of 40°C. On the other hand, the composition of Example 1 showed a slight increase in particle size when the temperature was raised to 25° C. at pH 5.0, and a significant increase in particle size when the temperature was raised to 40° C. In other words, it is considered that the niosomes of Example 1 are destabilized and undergo a structural change at the temperature and pH of the skin surface.
[0048] The images in Figures 4 and 5 reveal the following: At a pH of 6.5, the niosomes contained in the composition of Example 1 maintain a uniform spherical shape (Figure 4). Even when enlarged, uniform spherical vesicles can be observed (see the enlarged image in Figure 4). On the other hand, at pH 5.0, the niosome particles swelled and the release of ceramide crystals was confirmed (Figure 5).
[0049] From the above test results, it was found that the composition containing the niosome of the present invention has extremely stable niosomes at pH 6.5, but when placed at the pH of the skin surface, the niosomes collapse and release ceramide. This is because the niosomes contained in the composition of Example 1 contain a copolymer.
[0050] <Test Example 5: Ceramide release measurement test> 1. Test Method The compositions containing niosomes of Example 1 and Comparative Example 1 were stored under the conditions of pH 5.0 and in thermostatic storage conditions of 5°C, 25°C, and 40°C, and after 8 hours, each composition was filtered through a membrane filter with a pore size of 0.45 μm to remove the released and crystallized ceramide. The ceramide concentration in the filtrate was measured using HPLC. The ceramide was measured by quantifying it by a conventional method using a liquid chromatography column (CAPCELLPAK MGIII: manufactured by Osaka Soda Co., Ltd.).
[0051] 2.Results The results of the test for measuring the amount of ceramide released from niosomes (the results of measuring the amount of ceramide in the filtrate) are shown in Figure 6. As shown in Figure 6, the amount of ceramide in the filtrate of the composition is clearly reduced. This indicates that the amount of ceramide in the niosomal state is reduced. In other words, the niosomes of Example 1 release ceramide in a temperature-dependent manner under conditions of pH 5.0. When the temperature rises to 25°C, the amount of release increases, and the effect is maximized at 40°C. These test results revealed that the composition of Example 1 released ceramide in a temperature-dependent manner under the pH conditions of the skin.
[0052] <Test Example 6: Evaluation of the effect on stratum corneum lamella formation by continuous use test on humans> 1. Test Method The composition of Example 1 and the composition of Comparative Example 1 were applied twice a day to the inside of the right forearm (composition of Example 1) and the inside of the left forearm (composition of Comparative Example 1) by three subjects for one week, and the evaluation was performed. In evaluating the effect, the stratum corneum lamellae were quantified before and after continuous use to confirm the effect. The stratum corneum lamellae were quantified by tape stripping samples taken before and after the start of continuous use, and image analysis was performed using a microscope. The area of the lamellae relative to the area of the stratum corneum cells was calculated as the lamellar ratio. The change (increase) in this lamellar area represents the effect of lamellar formation.
[0053] 2.Results The measurement results of the lamellar ratio are shown in FIG. The measurement results are the average value and standard deviation of the lamellar ratios of three subjects. As shown in Fig. 7, the lamellar ratio increased significantly in Example 1. On the other hand, in Comparative Example 1, lamellar formation was hardly promoted even though the ceramide content was as high as in the Examples.
[0054] <Test Example 7: Evaluation of moisturizing effect by continuous use test on humans> 1. Test Method As in Test Example 5, the composition of Example 1 and the composition of Comparative Example 1 were applied to the inside of the right forearm (composition of Example 1) and the inside of the left forearm (composition of Comparative Example 1) of three subjects, respectively, and an evaluation was performed. The skin moisturizing effect was evaluated by measuring the conductance of the applied area 30 minutes, 1 hour, 2 hours, 3 hours, and 4 hours after application using a moisture meter. The increase in conductance compared to before application was regarded as the skin moisturizing effect.
[0055] 2.Results The increase in conductance (μS) from the conductance value before use is plotted against the measurement time on the X-axis in Figure 8. The measurement results are the average and standard deviation of the conductance change for three subjects. Up to 30 minutes after application, there was no significant difference between the compositions of Example 1 and Comparative Example 1, but after 1 hour, the composition of Comparative Example 1 showed a large decrease in conductance value over time. On the other hand, when the composition containing the niosome of the present invention was applied, the decrease in conductance was gradual. In other words, Example 1 of the present invention was able to maintain moisturizing properties for a long time.
[0056] <Examples 2 to 7> Examples 2 to 7 were prepared in the same manner as in Example 1 and tested (stability and responsiveness to pH and temperature). The test results were equivalent to those of Example 1. The compositions and results are shown in Table 3 below. In the columns for stability and responsiveness to pH and temperature, the symbol "◯" indicates that the results are equivalent to those of Example 1.
[0057] [Table 3]
Claims
1. A composition for external use on the skin comprising niosomes comprising the following (A) to (F): (A) is a copolymer having a structure in which a portion of the carboxyl groups of polymethacrylic acid is esterified with methoxydiethylene glycol and lauroxytetraethylene glycol, and has an average molecular weight of 1,000 to 1,000,000, and the content is 0.1 to 10.0 parts by mass per part by mass of (B). (B) Ceramide containing ceramide 2 or 3 (C) A nonionic surfactant containing polyoxyethylene hydrogenated castor oil and fatty acid sorbitan, and containing fatty acid sorbitan in a mass ratio of 0.4 to 16 when the amount of polyoxyethylene hydrogenated castor oil is 1, and the content is 0.5 to 20.0 parts by mass per 1 part by mass of (B). (D) dipropylene glycol and / or pentylene glycol, In the case where dipropylene glycol is contained without pentylene glycol, dipropylene glycol is contained in an amount of 20 parts by mass or more per 1 part by mass of (B); In the case where pentylene glycol is contained without dipropylene glycol, 15 parts by mass or more of pentylene glycol per 1 part by mass of (B) is used. (E) Water (F) pH adjuster
2. The composition for external use on skin according to claim 1, wherein the polyoxyethylene hydrogenated castor oil is polyoxyethylene hydrogenated castor oil having an average degree of polymerization of polyoxyethylene chains of 60 to 100, and the fatty acid sorbitan is one or more selected from sorbitan sesquiisostearate, sorbitan sesquioleate, and sorbitan oleate.
3. 3. The composition for external application to the skin according to claim 1 or 2, which is in the form of a skin lotion.
4. A niosome formed by combining a copolymer having a structure in which some of the carboxyl groups of polymethacrylic acid are esterified with methoxydiethylene glycol and lauroxytetraethylene glycol with ceramides in a bilayer membrane.
5. The niosome according to claim 4, wherein the copolymer having a structure in which a portion of the carboxyl groups of polymethacrylic acid is esterified with methoxydiethylene glycol and lauroxytetraethylene glycol is a random copolymer.
6. The niosome according to claim 5, wherein the methoxydiethylene glycol (MDEGMA) portion and the lauroxytetraethylene glycol (LTEGMA) portion of the copolymer having a structure in which a portion of the carboxyl groups of polymethacrylic acid is esterified with methoxydiethylene glycol and lauroxytetraethylene glycol are 50 to 70% and 2 to 10%, respectively, when the entire carboxyl groups of polymethacrylic acid are taken as 100%.
Citation Information
Patent Citations
Vesicular dispersion of nonionic surface active agent
JP1984016534A
Method for preparation of reconstructed skin supplemented in ceramid 7 and / or 5.5, composition based on lamellar lipid vesicle containing at least one derivative of ceramid 7 and / or 5.5 family introduced into the vesicle, and use thereof
JP2007246538A
A ceramide-containing water-in-oil emulsifier for topical skin preparations.
JP2010513221A
TEMPERATURE- AND pH-RESPONSIVE COPOLYMER, AND LIPOSOME COMPLEX
JP2015209494A
Tetrahydronaphthyridinylpropionic acid derivatives and methods of use thereof
JP2018514568A
